U.S. Health Care REITs Stock News

Establishment Labs Holdings (ESTA) has drawn fresh attention after recent share price moves, with the stock up about 11% over the past month and roughly 25% in the past 3 months. See our latest analysis for Establishment Labs Holdings. The recent 7 day share price return of 9.74% and 90 day share price return of 24.95% come on top of a 1 year total shareholder return of 106.18%, pointing to momentum that has been building rather than fading. If you are comparing ESTA with other faster growing...

Recently, Zacks upgraded Brink's to a Rank #2 (Buy), citing a positive shift in analyst earnings estimates and a stronger earnings outlook for the company. This ratings change highlights how revisions to profit expectations can shape investor perception of Brink's evolving cash-management and digital services business model. Next, we'll examine how this more optimistic earnings outlook might influence Brink's broader investment narrative built around AMS and digital solutions. The future of...

Earlier this week, Vornado Realty Trust reported that PENN 2 in New York’s PENN DISTRICT is now 90% leased after signing 10–12 year full-floor agreements with technology tenants Veeva and Altana AI, which is establishing its new headquarters there. This leasing progress at a flagship redevelopment, coupled with increased interest across office REITs, highlights how high-quality, amenity-rich assets may be attracting tenants even as the broader office sector adjusts to new working...

On June 8, 2026, PTC Therapeutics announced that board member Alethia Young resigned to focus on other work commitments, while simultaneously entering a consulting agreement that keeps her advising the company through June 8, 2027. This move comes as PTC Therapeutics reports record revenue driven by strong global uptake of SEPHIENCE, underscoring the company’s emphasis on continuity of commercial and advisory expertise. We’ll now examine how record SEPHIENCE-driven revenue, alongside Alethia...

In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities. The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity. We’ll now examine how Maximus’ expanded term loan capacity and planned...

CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year. See our latest analysis for CG Oncology. Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very...

Rising tensions between the US and Iran, self defense strikes, and related crude supply disruptions have pushed oil prices higher, putting Diamondback Energy (FANG) firmly back on investors’ radar as a key US shale producer. See our latest analysis for Diamondback Energy. Short term, the stock has been choppy, with the share price falling 6.67% over the past week even as it gained 11.04% over 90 days and delivered a 35.39% total shareholder return over the past year. This pattern suggests...

Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress. These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts. We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these...

In recent days, Clear Street analyst Tim Moore highlighted Willdan Group’s potential upside, citing expected revenue and adjusted EBITDA growth from power grid modernization and rising demand for energy-efficient and AI datacenter solutions, while company insiders sold about US$6.1 million of stock over the past three months. This combination of bullish analyst commentary on AI datacenter exposure and concurrent insider selling offers a contrasting signal about management’s and the market’s...

On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal. This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...

Popular (BPOP) is back in focus after recent analyst commentary highlighted upward revisions to earnings estimates and a strong momentum style score. This has drawn attention to how these signals may influence sentiment around its stock. See our latest analysis for Popular. Recent price action has been supportive for that improving sentiment, with a 90 day share price return of 19.32% and a 1 year total shareholder return of 51.92%. Multi year total shareholder returns above 100% point to...

Nabors Industries recently faced increased investor attention after geopolitical tensions and sector-wide energy volatility raised concerns about operational risks, particularly in the Gulf region. At the same time, some analysts view Nabors as trading at a substantial discount to their fair value estimates, despite ongoing margin and capital intensity headwinds. We’ll now examine how rising geopolitical risk in key operating regions could influence Nabors Industries’ existing investment...

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with anticipated earnings growth of 18% per annum in the coming years. In this fluctuating environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.

Over the last 7 days, the United States market has experienced a 4.1% drop, yet it remains up by 21% over the past year with earnings forecasted to grow by 18% annually. In this context of fluctuating market conditions, companies with high insider ownership and strong revenue growth potential can offer intriguing opportunities for investors seeking stability and alignment of interests between management and shareholders.

Over the last 7 days, the United States market has dropped 4.1%, but it remains up by 21% over the past year, with earnings expected to grow by 18% annually in the coming years. Investing in penny stocks—often smaller or newer companies—can still offer growth opportunities, especially when these stocks are backed by strong financial health. We'll explore several penny stocks that stand out for their financial strength and potential for long-term success.

Over the last 7 days, the United States market has dropped by 4.1%, though it has risen by an impressive 21% over the past year, with earnings forecasted to grow annually by 18%. In this dynamic environment, identifying dividend stocks that offer reliable income and potential for growth can be a prudent strategy for investors seeking stability amidst market fluctuations.

EHang Holdings Limited reported weaker Q1 2026 results on June 9, with CNY 25.66 million in sales and a CNY 125.96 million net loss, while reaffirming its 2026 revenue guidance of RMB 600 million. Alongside these results, the company authorized a new US$30 million share repurchase program funded from existing cash, signaling management’s confidence as it advances pilotless eVTOL commercialization. We’ll now examine how reaffirmed 2026 revenue guidance, despite soft Q1 sales, affects EHang’s...

Recently, commentary highlighted that Global Partners’ extensive fuel distribution network could benefit from higher energy prices linked to renewed geopolitical tensions and inflation pressures. This focus on its exposure to rising commodity prices adds a new angle to how the market views Global Partners’ earnings sensitivity to macro shocks. Now we’ll examine how this increased attention on Global Partners’ leverage to higher energy prices may reshape its broader investment...

With inflation pressures, energy shocks and rate expectations keeping markets on edge, many investors are looking for companies that already show high return on equity, sound past performance and robust balance sheets. Instead of chasing short term stories tied to every data release or central bank headline, this approach focuses on businesses that appear financially resilient and efficient. Using our Solid Balance Sheet and Fundamentals screener, this article highlights 3 stocks that...

In early June 2026, Air Products and Chemicals marked the completion of a US$70 million expansion of its Missouri Manufacturing and Logistics Center in Maryland Heights, adding more than 70 hires to support rising demand in biogas, hydrogen recovery, aerospace nitrogen, and cleaner marine fuels. This expansion is Air Products Membrane Solutions' largest single-site investment to date, underlining how energy transition applications are becoming a central focus of the company’s industrial gas...

Wholesale inflation just surprised to the upside, with May PPI and energy costs running hotter than expected, and the market now leaning toward higher for longer interest rates. That mix can pressure many stocks, but it can also highlight companies where dividend income and relatively resilient demand look more appealing. This article focuses on large, established dividend payers that are directly exposed to this inflation story. It will walk through 3 stocks from our Inflation-Resilient...

Global growth warnings, inflation pressures, and conflict driven supply risks are pushing commodity and natural resource stocks back into the spotlight. With the World Bank projecting 2.5% global growth for 2024 and highlighting the risk of sharper slowdowns, investors are again weighing how exposure to energy, materials, and agriculture related businesses might respond to higher price volatility and prolonged tight financial conditions. This article highlights three large, financially stable...

In early June 2026, OPKO Health amended its agreement with Nicoya Therapeutics, securing a 15% equity stake while preserving eligibility for up to US$115 million in potential RAYALDEE-related payments in Greater China and surrounding territories. This deeper Nicoya partnership adds an ownership position on top of royalties and milestones, tying OPKO Health more directly to RAYALDEE’s regional commercialization outcomes. Next, we’ll examine how OPKO’s new 15% Nicoya stake and reshaped...

Earlier this month, The Hanover Insurance Group, Inc. declared a quarterly dividend of US$0.95 per share, payable on June 26, 2026, and also participated in the Morgan Stanley US Financials Conference 2026 in New York on June 9, 2026. Together with its appearance at a major financials conference, Hanover’s recent recognition by Zacks as a top-ranked value stock highlights growing analyst attention to its valuation and earnings profile. With Hanover’s upgraded earnings estimates now in focus,...